Safety Lead-In Study of a Repurposed Drug Added to the Combination of Len Plus Pem

NCT05106127 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

28

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Endometrial Cancer

Interventions

DRUG: EG-007
DRUG: Pembrolizumab 100 mg/4 mL (25 mg/ml) Injection
DRUG: Lenvatinib Capsules

Sponsor

Evergreen Therapeutics, Inc.